Skip to main content
. 2022 Jul 6;10(7):e004668. doi: 10.1136/jitc-2022-004668

Table 2.

Objective response rate (ORR) to first exposure checkpoint inhibitors

N (%) Anti-PD-1 (N=180) Anti-PD-1 +Ipilimumab (N=58) Ipilimumab (N=82)
ORR, % 26 43 15
CR 22 (12) 8 (14) 4 (5)
PR 25 (14) 17 (29) 8 (10)
SD 31 (17) 7 (12) 14 (17)
PD 102 (57) 26 (45) 56 (68)
OR (95% CI) 1 2.14 (1.16 to 3.97) 0.49 (0.24 to 0.97)
 P value 0.0004 0.0016

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.